Results from Arm A of Phase 1/2 DREAMM-6 trial: belantamab mafodotin with lenalidomide plus dexamethasone in patients with relapsed/refractory multiple myeloma

• Rakesh Popat,
• Bradley Augustson,
• Mercedes Gironella,
• Cindy Lee,
• Paul Cannell,
• Nashita Patel,
• Ravi S. Kasinathan,
• Rachel Rogers,
• Mehreen Shaikh,
• Amy Curry,
• Fernando Carreño,
• Sumita Roy-Ghanta,
• Joanna Opalinska,
• Hang Quach

Affiliations

Rakesh Popat

NIHR UCLH Clinical Research Facility, University College London Hospitals NHS Foundation Trust

Bradley Augustson

Sir Charles Gairdner Hospital and Linear Clinical Research

Mercedes Gironella

Department of Hematology, University Hospital Vall d’Hebron

Cindy Lee

Royal Adelaide Hospital

Paul Cannell

Department of Haematology, Fiona Stanley Hospital

Nashita Patel

GSK

Ravi S. Kasinathan

GSK

Rachel Rogers

GSK

Mehreen Shaikh

GSK

Amy Curry

GSK

Fernando Carreño

GSK

Sumita Roy-Ghanta

GSK

Joanna Opalinska

GSK

Hang Quach

University of Melbourne, St. Vincent’s Hospital Melbourne